ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,164.12
-0.19%
Dow Jones
39,118.86
-0.12%
Gold vs US Dollar
2,323.88
-0.07%
Brent Oil
85.055
-0.06%
Bitcoin
62,680.42
0.02%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Summit Therapeutics Inc (SMMT)

  7. Summit Therapeutics Inc (SMMT) News

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateTimeSourceHeadlineSymbolCompany
27/06/202421:15Business WireSummit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of DirectorsNASDAQ:SMMTSummit Therapeutics Inc
18/06/202422:14Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SMMTSummit Therapeutics Inc
17/06/202422:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
13/06/202419:03Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SMMTSummit Therapeutics Inc
03/06/202411:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
03/06/202411:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
03/06/202410:30Business WireSummit Raises $200 Million; Also Expands License Territories for IvonescimabNASDAQ:SMMTSummit Therapeutics Inc
01/06/202413:00Business WireIvonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMANASDAQ:SMMTSummit Therapeutics Inc
01/06/202400:00Business Wire Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus ChemotherapyNASDAQ:SMMTSummit Therapeutics Inc
30/05/202423:00Business WireSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SMMTSummit Therapeutics Inc
30/05/202421:48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
30/05/202419:29Business WireIvonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in ChinaNASDAQ:SMMTSummit Therapeutics Inc
24/05/202413:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
13/05/202413:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
13/05/202412:48Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SMMTSummit Therapeutics Inc
01/05/202412:00Business WireSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024NASDAQ:SMMTSummit Therapeutics Inc
24/04/202421:30Business WireSummit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024NASDAQ:SMMTSummit Therapeutics Inc
11/04/202421:30Business WireSummit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of DirectorsNASDAQ:SMMTSummit Therapeutics Inc
10/04/202412:00Business WireSummit Therapeutics to Present at the Stifel 2024 Targeted Oncology ForumNASDAQ:SMMTSummit Therapeutics Inc
22/03/202411:00Business WirePromising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024NASDAQ:SMMTSummit Therapeutics Inc
14/03/202411:00Business WireIntracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024NASDAQ:SMMTSummit Therapeutics Inc
05/03/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
05/03/202412:00Business WireSummit Therapeutics to Present at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
20/02/202413:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
20/02/202412:55Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SMMTSummit Therapeutics Inc
20/02/202412:32Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SMMTSummit Therapeutics Inc
20/02/202412:00Business WireSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023NASDAQ:SMMTSummit Therapeutics Inc
15/02/202422:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
14/02/202421:35Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:SMMTSummit Therapeutics Inc
14/02/202415:29Business WireSummit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024NASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT

Your Recent History

LSE
GPM
Golden Prospect Precious...
LSE
BMN
Bushveld Minerals
LSE
GGP
Greatland Gold
LSE
BARC
Barclays
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved